When was Lung Therapeutics founded?

Lung Therapeutics was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Where is Lung Therapeutics located?

Lung Therapeutics is headquartered in Austin, United States.

Who is the current CEO of Lung Therapeutics?

Brian Windsor of Lung Therapeutics.

Is Lung Therapeutics a funded company?

Lung Therapeutics is a funded company, having raised a total of $107M across 8 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Sep 10, 2014.

When was the latest funding round of Lung Therapeutics?

Lung Therapeutics' latest funding was a $***** Series C round on Apr 04, 2022, with participation from 0 investor. Its primary sector is Rare Diseases. In United States, the Rare Diseases sector has seen $1.05B in funding in 2026 to date.

Where does Lung Therapeutics rank among its competitors?

Lung Therapeutics ranks 105th amongst 283 active competitors, of which 77 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was BridgeBio, which secured $200M in Apr, 2024.

Who are the top competitors of Lung Therapeutics?

Lung Therapeutics' top competitors include BridgeBio, Alnylam and PTC Therapeutics. Among them, BridgeBio secured the most recent funding round in April, 2024.

Lung Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Lung Therapeutics is an acquired company based in Austin (United States), founded in 2013. It operates as a Therapeutics for rare lung diseases include Pleural Effusion, Acute Lung Injury and Idiopathic Pulmonary Fibrosis.. Lung Therapeutics has raised $107M in funding from investors like Steelhead Capital Management, Austin Technology Incubator and Bios Partners. The company has 283 active competitors, including 77 funded and 98 that have exited. Its top competitors include companies like BridgeBio, Alnylam and PTC Therapeutics.

Company Details

Lung Therapeutics is targeting niche, orphan drug indications for lung injury and disease, with an emphasis on fibrosis. Its current efforts are focused on a severe complication of pneumonia, called loculated pleural effusion, a condition where fluid has built up in the chest cavity surrounding the lungs and fibrinous scar tissue in the pleural cavity blocks fluid drainage. Its first product, LTI-01 (single chain urokinase plasminogen activator, or scuPA), is being studied for safe clearance of fibrinous scar tissue in patients with loculated pleural effusion. It has received more than $17M from NIH.

Website: lungtx.com
Social

Key Metrics

Founded Year

2013

Location

Austin, United States

Stage

Acquired

Total Funding

$107M in 8 rounds

Latest Funding Round

Series C, Apr 04, 2022, $*****

Investors

Steelhead Capital Management & 5 more

Ranked

105^th among 283 active competitors

Similar Companies

BridgeBio & 317 more

Exit Details

Acquired by Aileron Therapeutics (Oct 31, 2023)

View Lung Therapeutics' full profile

Lung Therapeutics got acquired by Aileron Therapeutics on Oct 31, 2023.

Click here to take a look at Lung Therapeutics's acquisition in detail

Lung Therapeutics has raised a total funding of $107M over 8 rounds. Its first funding round was on Sep 10, 2014. Lung Therapeutics has 6 institutional investors.

Here is the list of recent funding rounds of Lung Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 04, 2022	3273038	Series C	5038229	9817350	4028069	7232314
Oct 31, 2019	8284471	Series C	1384258	9901934	4904443	9592772
May 24, 2019	2640795	Series C	4509294	7624476	3408005	3792317

Access funding benchmarks and valuations. Sign up today!

View details of Lung Therapeutics's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Lung Therapeutics include BridgeBio, Alnylam and PTC Therapeutics. Here is the list of Top 10 competitors of Lung Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	71/100
7th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
8th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
9th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 9 others	70/100
10th	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
105th	Lung Therapeutics 2013, Austin (United States), Acquired	Therapeutics for rare lung diseases include Pleural Effusion, Acute Lung Injury and Idiopathic Pulmonary Fibrosis.	$107M	Bios Partners, Sea Purity Investments & 4 others	45/100